跳至主導覽 跳至搜尋 跳過主要內容

Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)

  • Hung Ming Wang
  • , Pei Jen Lou
  • , Muh Hwa Yang
  • , Tein Hua Chen
  • , Ming Yu Lien
  • , Jin Ching Lin
  • , Jo Pai Chen
  • , Wei Chen Lu
  • , Hsueh Ju Lu
  • , Tai Lin Huang
  • , Chia Jui Yen
  • , Shang Yin Wu
  • , Hui Ching Wang
  • , Meng Che Hsieh*
  • *此作品的通信作者
  • National Taiwan University
  • Veterans General Hospital-Taipei
  • China Medical University Taichung
  • Changhua Christian Hospital
  • Chung Shan Medical University
  • Chang Gung University
  • National Cheng Kung University
  • Kaohsiung Medical University
  • I-Shou University

研究成果: 期刊稿件 › 文章 › 同儕審查

1 引文 斯高帕斯(Scopus)

摘要

BACKGROUND: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs.

OBJECTIVE: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy.

PATIENTS AND METHODS: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed.

RESULTS: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS.

CONCLUSIONS: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.

原文英語
頁(從 - 到)51-58
頁數8
期刊Targeted Oncology
卷19
發行號1
DOIs
出版品狀態已出版 - 01 2024

文獻附註

© 2024. The Author(s).

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)」主題。共同形成了獨特的指紋。

引用此